ImmunOs Therapeutics AG is developing the next generation of immunotherapies that have a role in the innate immune system for cancer and autoimmune diseases. The company is developing therapies that not only have direct anti-tumor effects but also remodel the tumor microenvironment to enhance the efficacy of existing immunotherapies. This portfolio of next generation, novel immunomodulatory proteins target diverse and key immunoregulatory receptors. Our lead program iosH2, now advancing to Phase 1 studies, is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and thereby activates anti-tumor responses in multiple cancers with monotherapy and in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1, CD47) and costimulatory agonists (e.g. 4-1BB).
View Top Employees from ImmunOs Therapeutics AGWebsite | http://www.immunostherapeutics.com |
Revenue | $5 million |
Employees | 30 (24 on RocketReach) |
Founded | 2014 |
Address | Wagistrasse 18, Schlieren, Zurich 8952, CH |
Technologies |
HTML,
PHP,
Twitter
+8 more
(view full list)
|
Industry | Biotechnology, Business Services General, Business Services, Science and Engineering, Pharmaceutical, Health Care |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 541714 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies |
Looking for a particular ImmunOs Therapeutics AG employee's phone or email?
The ImmunOs Therapeutics AG annual revenue was $5 million in 2024.
Sean Smith is the CEO of ImmunOs Therapeutics AG.
24 people are employed at ImmunOs Therapeutics AG.
ImmunOs Therapeutics AG is based in Schlieren, Zurich.
The NAICS codes for ImmunOs Therapeutics AG are [541714, 541, 54, 5417, 54171].
The SIC codes for ImmunOs Therapeutics AG are [873, 87].